PharVision Advisers’s Monro MNRO Stock Holding History

PharVision Advisers’s Portfolio MNRO Stock Details MNRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,188	Closed	-$501K	–	430
2024 Q4	$501K	Buy	+20,188	New	+$553K	0.42%	42

Other funds holding MNRO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCPM

Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PharVision Advisers's MNRO Position: Q1 2025 in Review

PharVision Advisers sold out of Monro (MNRO) in Q1 2025, closing a stake of 20,188 shares — an estimated $501K sold.

PharVision Advisers first reported a position in MNRO in Q4 2024 and held it in 1 quarter. The position peaked at $501K in Q4 2024. 180 funds tracked by Wall St. Rank hold MNRO as of Q1 2025.

PharVision Advisers reported no remaining Monro position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 20,188 Monro shares in Q1 2025, an estimated $501K.
PharVision Advisers first reported a position in Monro in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Monro position peaked at $501K in Q4 2024.
180 funds tracked by Wall St. Rank held Monro as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.